Younes Mohamed, Neffati Fadoua, Touzi Mongi, Hassen-Zrour Saoussen, Fendri Yosr, Béjia Ismail, Ben Amor Adel, Bergaoui Naceur, Najjar Mohamed Fadhel
Rheumatology Department, Monastir Public Health Facility, Monastir, Tunisia.
Joint Bone Spine. 2007 Oct;74(5):472-6. doi: 10.1016/j.jbspin.2006.10.009. Epub 2007 Jul 6.
Whereas the systemic effects of glucocorticoid therapy have been extensively reported, little is known about those of local glucocorticoid injections. The objective of this study was to look for systemic effects of local glucocorticoid injections at two sites in diabetic and non-diabetic patients.
We studied 29 patients (18 women and 11 men with an age range of 18-86 years). The injection site was the epidural space in 18 patients (4 with and 14 without diabetes) with disk-related sciatica and the shoulder in 11 patients (8 with and 3 without diabetes) with frozen shoulder. Each patient was given three injections of 1.5 ml cortivazol (5.625 mg of cortivazol or about 85 mg prednisone-equivalent per injection and about 250 mg prednisone-equivalent in all), at 3-day intervals. Of the 12 patients with diabetes, 2 were on insulin therapy. At baseline and at the post-treatment visits 1, 7, and 21 days after the third injection, the following tests were done: plasma cortisol and ACTH at 8 am, urinary free cortisol excretion in 24 hours, fasting and postprandial blood glucose, serum cholesterol and triglycerides, and serum sodium and potassium. Blood pressure was measured at each visit.
Mean systolic blood pressure increased significantly between baseline (123+/-10 mmHg) and the first two post-treatment visits (day 1, 127+/-9 mmHg; and day 7, 128+/-10 mmHg) but returned to baseline values by the third post-treatment visit (day 21). Mean postprandial blood glucose was significantly higher at the day 1 post-treatment visit (10.1+/-5.4 mmol/l) than at baseline (7.5+/-2.9 mmol/l). At the day 7 post-treatment visit, blood glucose remained significantly elevated compared to baseline in the 12 diabetic patients (13.9+/-4.8 mmol/l versus 9.4+/-3.3 mmol/l at baseline). In both the overall population and the various subgroups, plasma cortisol and ACTH and urinary free cortisol were markedly reduced at the day 1 and day 7 post-treatment visits, compared to baseline. At the day 21 visit, these variables were diminished in the group given epidural injections, whereas plasma cortisol and ACTH were normal in the group treated intra-articularly. No significant variations were noted for fasting blood glucose or for serum levels of cholesterol, triglycerides, sodium, and potassium.
The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection. Systolic blood pressure increased transiently. Elevations in postprandial glucose levels lasted longer in diabetic than non-diabetic patients.
尽管糖皮质激素治疗的全身效应已被广泛报道,但局部注射糖皮质激素的全身效应却鲜为人知。本研究的目的是探寻局部注射糖皮质激素在糖尿病患者和非糖尿病患者两个部位的全身效应。
我们研究了29例患者(18名女性和11名男性,年龄范围为18 - 86岁)。18例因椎间盘相关坐骨神经痛患者(4例糖尿病患者和14例非糖尿病患者)的注射部位为硬膜外腔,11例肩周炎患者(8例糖尿病患者和3例非糖尿病患者)的注射部位为肩部。每位患者每隔3天接受3次1.5毫升可的唑注射(每次注射5.625毫克可的唑,约相当于85毫克泼尼松等效剂量,总共约250毫克泼尼松等效剂量)。12例糖尿病患者中,2例接受胰岛素治疗。在基线以及第三次注射后1天、7天和21天的随访时,进行以下检查:上午8点的血浆皮质醇和促肾上腺皮质激素、24小时尿游离皮质醇排泄量、空腹和餐后血糖、血清胆固醇和甘油三酯以及血清钠和钾。每次随访时测量血压。
平均收缩压在基线时(123±10 mmHg)与前两次治疗后随访时(第1天,127±9 mmHg;第7天,128±10 mmHg)显著升高,但在第三次治疗后随访时(第21天)恢复到基线值。治疗后第1天的平均餐后血糖(10.1±5.4 mmol/L)显著高于基线时(7.5±2.9 mmol/L)。在治疗后第7天随访时,12例糖尿病患者的血糖仍显著高于基线水平(13.9±4.8 mmol/L,而基线时为9.4±3.3 mmol/L)。在总体人群和各个亚组中,与基线相比,治疗后第1天和第7天的血浆皮质醇、促肾上腺皮质激素和尿游离皮质醇均显著降低。在第21天随访时,硬膜外注射组的这些变量有所降低,而关节内注射组的血浆皮质醇和促肾上腺皮质激素正常。空腹血糖以及血清胆固醇、甘油三酯、钠和钾水平未观察到显著变化。
三次局部注射可的唑后,促肾上腺皮质轴受到抑制,硬膜外注射后这种抑制持续超过21天,关节内注射后恢复更快。收缩压短暂升高。糖尿病患者餐后血糖升高持续时间比非糖尿病患者更长。